Sunstone Therapies has launched a new clinical trial evaluating group MDMA-assisted therapy for veterans living with PTSD. Supported by funding from the State of Maryland and Reason for Hope, the study will compare individual and group therapy models to assess safety, feasibility, and scalability. The research aims to expand access to evidence-based mental health care for veterans while generating critical insights into how psychedelic-assisted therapy may be delivered more effectively in the future.
Sunstone’s newest IIT offers veterans with PTSD access to breakthrough MDMA-assisted therapy research in both group and individual formats.
As psychedelic-assisted therapies continue advancing through clinical research, understanding how they fit within existing mental health care systems is increasingly important. This article explores psychedelic-assisted therapy as a specialty intervention that can complement ongoing psychotherapy and psychiatric care through collaborative treatment models, referral pathways, and continuity of care. Discover how these treatments may help patients become more emotionally flexible and engaged when traditional approaches alone are not enough.
What happens when an oncologist and a mortician discuss the mystery of death? Dr. Manish Agrawal joins the Death And podcast to bridge the gap between clinical rigor and human mystery. From the “collusion of denial” to the “infinity” found between birth and death, discover how psychedelic-assisted care invites patients back into their own experience to find peace and connection.
Dr. Manish Agrawal, CEO of Sunstone Therapies, joined Great Day Washington to discuss adjustment disorder—a common but frequently overlooked emotional response to serious illnesses like cancer, MS, and Parkinson’s. While modern medicine excels at treating physical symptoms, Dr. Agrawal highlights the “collusion of denial” that often leaves patients to navigate emotional upheaval in silence. Learn how Sunstone is addressing this critical gap through the REKINDLE Phase 2 study, an innovative clinical trial evaluating an investigational treatment for psychological distress in patients facing life-altering diagnoses.
Why veterans’ trauma requires new therapeutic approaches.
National Geographic recently highlighted emerging research on psilocybin-assisted therapy for patients facing advanced cancer and end-of-life distress. The article explores how psychedelic-assisted therapy may help reduce depression, anxiety, and existential suffering when delivered within structured clinical settings.
Sunstone Therapies is working to set the industry standard for high quality training that prepares mental health professionals to work safely, ethically, and effectively in psychedelic therapy research.
Researchers from Sunstone Therapies, Dana-Farber Cancer Institute, Harvard Medical School, and the University of Vermont have published new findings that deepen understanding of how psilocybin-assisted group therapy can help people with cancer and depression navigate profound existential challenges.